In particular, genetic or pharmacologic inhibition of vascular endothelial growth factor (VEGF) signaling reduces vascular growth, decreases alveolar formation and contributes to PAH [11, 13, 15, 16]. This evidence concerns the gene VEGFA and pulmonary arterial hypertension.